Individualized prediction of lung-function decline in chronic obstructive pulmonary disease

Background: The rate of lung-function decline in chronic obstructive pulmonary disease (COPD) varies substantially among individuals. We sought to develop and validate an individualized prediction model for forced expiratory volume at 1 second (FEV1) in current smokers with mild-to-moderate COPD. Methods: Using data from a large long-term clinical trial (the Lung Health Study), we derived mixed-effects regression models to predict future FEV1 values over 11 years according to clinical traits. We modelled heterogeneity by allowing regression coefficients to vary across individuals. Two independent cohorts with COPD were used for validating the equations. Results: We used data from 5594 patients (mean age 48.4 yr, 63% men, mean baseline FEV1 2.75 L) to create the individualized prediction equations. There was significant between-individual variability in the rate of FEV1 decline, with the interval for the annual rate of decline that contained 95% of individuals being −124 to −15 mL/yr for smokers and −83 to 15 mL/yr for sustained quitters. Clinical variables in the final model explained 88% of variation around follow-up FEV1. The C statistic for predicting severity grades was 0.90. Prediction equations performed robustly in the 2 external data sets. Interpretation: A substantial part of individual variation in FEV1 decline can be explained by easily measured clinical variables. The model developed in this work can be used for prediction of future lung health in patients with mild-to-moderate COPD. Trial registration: Lung Health Study — ClinicalTrials.gov, no. NCT00000568; Pan-Canadian Early Detection of Lung Cancer Study — ClinicalTrials.gov, no. NCT00751660

[1]  Shinu Abraham,et al.  Lung-function trajectories leading to chronic obstructive pulmonary disease , 2015 .

[2]  E. Ford Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011. , 2015, Chest.

[3]  S. Lam,et al.  Plasma pro-surfactant protein B and lung function decline in smokers , 2015, European Respiratory Journal.

[4]  Mark A. Pitt,et al.  Model Evaluation and Selection , 2014 .

[5]  T. Prentice World Health Report , 2013 .

[6]  S. Lam,et al.  Probability of cancer in pulmonary nodules detected on first screening CT. , 2013, The New England journal of medicine.

[7]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[8]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[9]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[10]  MPH Dr. Stacey Sheridan MD,et al.  Framingham-based tools to calculate the global risk of coronary heart disease , 2007, Journal of General Internal Medicine.

[11]  N. Anthonisen,et al.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.

[12]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[13]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.

[14]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[15]  G. Owens The Lung Health Study. , 1996, Current opinion in pulmonary medicine.

[16]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[17]  W. Bailey,et al.  Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. , 1993, Controlled clinical trials.

[18]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[19]  M. Segal,et al.  Analysis of dose-response curves to methacholine. An approach suitable for population studies. , 1987, The American review of respiratory disease.

[20]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.